# Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer

> **NCT00003181** · PHASE2 · UNKNOWN · sponsor: **Hope Cancer Institute, Inc.** · enrollment: 35 (estimated)

## Conditions studied

- Kidney Cancer

## Interventions

- **BIOLOGICAL:** aldesleukin
- **BIOLOGICAL:** sargramostim
- **DRUG:** vinblastine sulfate

## Key facts

- **NCT ID:** NCT00003181
- **Lead sponsor:** Hope Cancer Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 1997-05
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2013-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00003181

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00003181, "Interleukin-2, Vinblastine, and GM-CSF in Treating Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00003181. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*